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Abstract 
Background 
Aortic insufficiency is increasingly recognized as a complication of left ventricular 
assist device (LVAD) support and may lead to clinical decompensation requiring 
correction. This article describes experiences in managing patients presenting with 
concomitant aortic insufficiency and with de novo aortic insufficiency following left 
ventricular assist device implantations. 
Methods 
All patients undergoing LVAD implantation between 2012 and 2014 were included 
in this retrospective analysis if aortic valve insufficiency was present on 
implantation or newly developed (de novo) after implantation. Moderate to severe 
aortic valve insufficiency was corrected at implantation. 
Results 
The data of 39 patients were included. At the time of LVAD implantation, moderate 
to severe aortic valve insufficiency was present in 3 patients and was corrected by 
bioprosthetic valve replacement (2 patients) and by bioprosthetic valve 
replacement associated with ascending aorta with hemi arch replacement with a 
graft due to ascending aortic aneurysm (one patient). Four patients developed 
moderate to severe aortic insufficiency after LVAD surgery. Treatment with 
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conservative medical management was successful in 3 patients. One patient 
underwent transcatheter aortic valve occlusion using an Amplatzer closure device 
after failure of medical management.  
Conclusions 
Concomitant aortic valve replacement with LVAD implantation is a safe and viable 
option in managing aortic valve insufficiency. De novo aortic insufficiency may lead 
to recurrent heart failure and presents a clinical treatment challenge following 
successful LVAD support; the most appropriate and effective treatment option 
awaits definition. 
Keywords: aortic insufficiency, left ventricular assist device, recurrent heart failure 
 
Introduction 
The number of advanced heart failure patients treated with mechanical ventricular 
assist devices for either bridge-to-transplant therapy or for permanent destination 
therapy is growing.1 This expansion led to an increase in the number of patients 
with concomitant valvular heart disease,2 and clinicians are now faced with 
adapting treatment plans to multi-diagnosis conditions. Whereas moderate to 
severe mitral valve regurgitation is common in advanced heart failure and can be 
successfully treated with left ventricular assist device (LVAD) implantation,3 aortic 
valve pathology, specifically moderate to severe aortic insufficiency (AI), is 
uncommon at the time of LVAD implantation. Pal and colleagues reported 
moderate to severe aortic insufficiency in only 4% of a series of 281 heart failure 
patients.4 Several studies have described the development of AI as well as the 
progression from mild AI resulting in increasing recirculation of blood volume 
(closed-loop mechanism with blood flowing from the LV through the LVAD into the 
aorta and back into the LV).5,6 This altered circulation path may be etiological in 
the recurrence of heart failure symptoms despite LVAD implantation. This article 
describes the treatment and interventions selected for heart failure patients 
presenting with concomitant aortic valve insufficiency and with de novo aortic valve 
insufficiency following LVAD implantations. 
Methods 
Medical records of all patients who underwent LVAD implantation between 
October 2012 and December 2014 were extracted from the Heart Failure Data 
Registry of Florida Hospital Orlando, USA, and were reviewed retrospectively. The 
analysis included data of all patients with moderate to severe aortic valve 
insufficiency at implantation time as well as data of all patients with normal aortic 
valve function who developed aortic valve insufficiency after LVAD implantation 
(de novo).  Moderate or more severe AI at LVAD implantation was corrected as 
recommended in the literature.5 Post-operative management included pump speed 
optimization to allow for adequate aortic valve opening. Progressive and de novo 
aortic regurgitation post LVAD implantation was addressed with medical 
management as first-line therapy.  
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Patients underwent standard pre- and intraoperative evaluation with transthoracic 
and transesophageal echocardiography (TTE, TEE), left and right heart 
catheterization, chest computer tomography, and pulmonary artery catheter 
evaluation. Patients with postoperative new onset AI and complications were 
assessed by TTE, right heart catheterization and LVAD interrogation for medical 
management optimization with VAD flow adjustment, diuresis, and hypertension 
control. 
Due to the retrospective nature of the study ethical approval was waived by Florida 
Hospital ethics committee prior to the analysis. All patients signed an informed 
consent form and agreed that their data will be archived anonymously at hospital 
and national data registries (e.g. INTERMACS) 
Results 
Data of 39 patients (21-76 years of age, 13% female, 23% bridge-to-transplant, 
77% destination therapy) were included in this retrospective analysis. Overall, 
patient 1-year survival was 89% with bridge-to-transplant VADs and 75% with 
destination VADs. 
Intraoperative TEE assessments revealed moderate to 2+ AI in three patients with 
a history of dilated cardiomyopathy (patients 1-3, Table 1). Two patients were 
considered for destination therapy and one patient was listed and bridged to heart 
transplantation. The destination therapy patients (patients 1 and 2) underwent 
bioprosthetic aortic valve replacement (21 and 23 mm standard Carpentier-
Edwards bioprosthetic valves [Edwards Lifesciences Corporation, Irvine, CA, 
USA]) combined with HeartMate II implantation (HM II; Thoratec Corporation, 
Pleasanton, CA, USA). They were connected to cardiopulmonary bypass through 
standard distal ascending aorta and right atrial cannulation and cooled down to 34° 
C. After LVAD implantation, a short period of antegrade hypothermic crystalloid 
arrest after aorta cross-clamping allowed standard aortic valve replacement 
through a hockey stick-like aortotomy 1.5 cm distal to the origin of the right 
coronary artery. After release of the cross-clamp and reperfusion of the heart, the 
outflow graft was trimmed to its appropriate length and sutured end-to-side to the 
ascending aorta using a partial occlusion clamp. The third patient presented with 
moderate AI and severe ascending aortic dilatation to 52 mm with a very thin aortic 
wall (patient 3). He underwent a relatively complex procedure consisting of aortic 
bioprosthetic valve replacement (Carpentier-Edwards bioprosthetic valve) with 
ascending and hemi aortic arch replacement using circulatory arrest together with 
LVAD implantation. The surgical strategy was similar as described for the two 
destination therapy patients followed by hemi arch replacement using deep 
hypothermic circulatory arrest and 30 mm tube graft prosthesis with a single 
sidearm. The LVAD outflow graft was sutured end-to-end to the sidearm of the 
vascular prosthesis. All three patients made an uneventful recovery and were 
monitored monthly with TTE in the program affiliated clinics. There were no 
complications related to the prosthetic aortic valve such as thrombosis, stroke, or 
valve degeneration. All three patients survived the first year following LVAD 
implantation. 
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Table 1. Patients with end-stage cardiomyopathy treated using aortic valve 
replacement and left ventricular assist devices 
Patient Gender Age 
(years) 
Cardio-
myopathy 
Procedure/d
evice 
Type of 
therapy 
Diagnosis of aortic 
insufficiency 
Medical 
manageme
nt of aortic 
insufficienc
y 
1 Male 70 Dilative AVR/HM II DT Time of implant No 
2 Male 68 Dilative AVR/HM II DT Time of implant No 
3 Male 56 Dilative Complex 
AVR/HVAD 
BTT Time of implant No 
4 Female 64 Dilative HM II DT 8 months  
postoperative 
Yes 
5 Male 70 Ischemic HM II DT 8 months  
postoperative 
Yes 
6 Male 58 Dilative HVAD BTT 8 months  
postoperative 
Yes + 
Heart 
transplant 
7 Male 74 Ischemic HM II DT 8 months 
 postoperative 
Yes + 
Amplatzer 
device  
 
AVR, aortic valve replacement; BTT, bridge-to-transplant; DT, destination therapy; 
HM, Heartmate; HVAD, HeartWare 
 
Eight months following LVAD implantation, four patients (patients 4-7, Table 1) 
presented with heart failure and AI onset (3 patients on HM II, one patient on 
HeartWare HVAD [HeartWare, Framingham, MA, USA]). Heart failure was 
recurrent and was attributable to the newly developed AI. The initial management 
was conservative with medical treatment including diuretics and vasodilators but 
also TTE-controlled LVAD interrogation, LVAD flow reduction through a decrease 
in pump speed until frequent aortic valve opening was documented. These 
conservative measures were successful in two of the four patients (patients 4 and 
5). The condition of the third patient (patient 6) deteriorated 14 months after an 
initial positive response to medical treatment and LVAD flow adjustments; he 
underwent orthotopic heart transplantation which was successful. In the fourth 
patient (patient 7), left-sided symptoms persisted and worsening shortness of 
breath was observed. Eleven months after HM II implantation as third-time 
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sternotomy for ischemic cardiomyopathy he presented with severe right and left 
heart failure, multiorgan dysfunction, and hepatorenal failure. De novo AI and 
clinical decompensation were diagnosed. A decrease of HM II flow through 
reducing RPM from 8800 RPM to 8200 RPM markedly attenuated the AI but 
medical optimization management was not successful. The patient required 
inotropic medications and mechanical ventilatory support for worsening right heart 
failure and pulmonary edema. Immediate pre-procedure hemodynamics were right 
arterial pressure 17 mmHg, pulmonary artery pressure 54/32 mmHg, pulmonary 
artery occlusion pressure 22 mmHg, left ventricular pressure 90/50 mmHg, left 
ventricular end-diastolic pressure 20 mmHg, and cardiac output 2.4 L/min. 
Ultimately, the patient underwent percutaneous transcatheter closure of the aortic 
valve with a multi fenestrated 30 mm Amplatzer Cribriform (AGA Medical Corp, 
Plymouth, MN, USA) closure device (reported as a case report7). Immediate post-
procedure hemodynamics were right arterial pressure 3 mmHg, pulmonary artery 
pressure 32/14 mmHg, pulmonary artery occlusion pressure 16 mmHg. 
Fluoroscopy and TTE confirmed the successful aortic valve closure. Under 
echocardiography, the LVAD flow was increased to 9400 RPM. Two weeks after 
the procedure, the patient remained stable with improved symptoms and functional 
status and without evidence of further AI or device migration. The patient was 
discharged after 34 days of rehabilitation and nutritional support and was 
monitored closely by the heart failure team. He did not achieve the same exercise 
tolerance level as observed before aortic valve closure. The patient expired 14 
months after LVAD implantation in a hospice following a fall and head trauma 
associated with intracranial bleeding.  
Discussion 
Aortic stenosis or insufficiency is uncommon in patients with advanced heart 
failure considered for LVAD implantation.4 The main concern lies in the initiation of 
LVAD support which can exacerbate pre-existing AI.8,9 It was suggested that LVAD 
implantations create a continuous transvalvular pressure gradient (aortic pressure 
over LV pressure) across the aortic valve leading to rare aortic valve openings 
throughout the cardiac cycle. This may lead to fibrous tissue deposits along the 
commissures of the leaflets, resulting in leaflet adherence, fusion, and retraction of 
the leaflet tips and generation of a central orifice.10 A closed aortic valve and 
limited antegrade blood flow can lead to stasis on the ventricular surface of the 
aortic valve generating thrombus formation and organization which further 
aggravates leaflet fusion.8,10 The transvalvular pressure gradient described above 
can result in regurgitant flow from aorta to LV through the central orifice. 
Pathophysiologically, this recirculating blood volume may result in the recurrence 
of heart failure symptoms. Given the potential for AI to progress after LVAD 
insertion, all moderate or greater degrees of AI at the time of implantation were 
corrected. Three patients successfully underwent concomitant bioprosthetic aortic 
valve replacement at the time of LVAD implantation. We are not in favor of LV 
outflow tract closure techniques such as coaptation stitches of the leaflet tips, 
buttressing stitches of the commissures, or a sutured circular patch or membrane 
plug technique. Although these simple repair techniques require a shorter period of 
cardioplegic arrest, they are limited, because they complicate cardiovascular 
support measures in case of device malfunction and pump failure. Furthermore, a 
subset of advanced heart failure patients unloaded by LVAD may experience a 
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return of cardiac function and become candidates for device weaning and 
explantation.11 We favor bioprosthetic aortic valve replacement as the treatment of 
choice for moderate or more severe AI given its low complication risks and reliable 
results and agree with the view that aortic valve provides a “bail-out” mechanism 
should acute LVAD malfunction occur.5 A subgroup analysis revealed a markedly 
lower long-term survival of patients undergoing LVAD and isolated aortic valve 
procedures, however, these patients were significantly sicker, older, and with 
increased right ventricular dysfunction.12 After multivariate adjustments, surgical 
aortic valve closure was associated with increased mortality when compared with 
aortic valve replacement in patient with AI who underwent LVAD insertion.13 
The development of aortic insufficiency was noted in 25% to 52% of patients by 1 
year of LVAD support.5 Thirty-six of 166 patients supported by LVAD for a median 
461 days developed moderate AI at a median 273 days after LVAD implantation.6 
AI development was more pronounced in continuous-flow compared with pulsatile-
flow LVAD.14 Newly developed AI after LVAD implantation affects device 
performance, leads to recurrent heart failure symptomatology, and impacts patient 
outcomes. In our series of heart failure patients supported by LVAD, de novo AI 
occurred in four patients in close follow-up ambulatory studies over an average of 
8 months. Serial echocardiography revealed intermittent aortic valve opening and 
pulsatile flow. First-line treatment included diuretics and oral vasodilators to control 
hypertension and to reduce gradients driving aortic valve insufficiency. 
Additionally, the selected pump speed setting was adjusted by echocardiography 
guidance to ensure sufficient circulatory support at rest while allowing intermittent 
aortic valve opening and maintaining normal LV dimensions. Three of the four 
patients showed a mild degree of LV myocardial recovery on echocardiography 
and associated increased ejection and pulsatility allowing a reduction in pump 
speed.  
Clinically significant de novo AI refractory to medical management and LVAD flow 
optimization is best treated with surgical AI correction or heart transplantation. In 
cases where conventional aortic valve replacement was of very high risk, 
percutaneous transcatheter aortic valve closure has been previously described in 
5 LVAD patients with de novo AI.15 The authors concluded that percutaneous 
transcatheter closure (if successfully employed) appears to be a safe and effective 
method to treat AI in patients with LVAD, a population often too sick to undergo 
reoperation for treatment. Although the results are encouraging, the technique 
needs to be studied in a larger cohort for long-term follow-up. The transcatheter 
aortic valve replacement might be another good option for these patients with de 
novo AI; it is, however, not yet approved by the Food and Drug Administration for 
AI. 
In summary, concomitant aortic valve surgery with LVAD implantation is safe and 
associated with a good outcome. De novo aortic insufficiency and regurgitation 
may lead to recurrent heart failure and remains a clinical treatment challenge 
following successful LVAD implantation and support. Most of the patient with de 
novo AI will respond to optimized medical therapy; the most appropriate and 
effective treatment option awaits definition. 
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